150例青海地区非小细胞肺癌患者表皮生长因子受体突变状态分析∗

摘要

Objective To explore the mutation status of epidermal growth factor receptor (EGFR)during the treatment process of non-small cell lung cancer(NSCLC)in Qinghai region.Methods The real-time fluorescence Taqman probe method was used and the PCR amplification in vitro was adopted.The clinical characteristics and EG-FR mutation status in 1 50 cases of advance NSCLC were retrospectively analyzed.Results In the sample detection of 1 50 NSCLC cases,EGFR mutation (exon18 )was in 2 cases with the mutation rate of 1.3%;EGFR mutation (exon1 9)was in 18 cases with the mutation rate of 12.0%;EGFR (exon20)was not detected;EGFR mutations (ex-on 21)was in 27 cases with the mutation rate of 18.0%.Conclusion The mutation rate of EGFR gene exon 1 9 and 21 (somatic mutation)is higher in NSCLC patients of Qinghai region.The EGFR-TKIs treatment is acceptable.%目的：探讨青海地区非小细胞肺癌(NSCLC)治疗过程中表皮生长因子受体(EGFR)突变状态。方法利用实时荧光 Taqman 探针法，采用 PCR 体外扩增，回顾性分析150例晚期 NSCLC 患者的临床特征、EGFR 突变状态。结果150例 NSCLC 患者标本检测发现 EGFR(exon18)突变2例，突变率1.3%；EGFR(exon19)突变18例，突变率12.0%；EGFR(exon20)未检测出；EGFR(exon21)突变27例，突变率18.0%。结论青海地区 NSCLC患者 EGFR 基因外显子19和21的突变(体细胞突变)率较高，可接受 EGFR-TKIs 治疗。